SCHEMBL811263

SCHEMBL811263

Cc1ccc2c(Nc3cc(OCc4cccc5ccccc45)ccc3Sc3ccc(O)cc3)ncnc2n1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.82
AKT2 P31751 1/20 0.82
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
KDR P35968 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PARP10 Q53GL7 2/20 0.35
PARP15 Q460N3 1/20 0.35
SPHK2 Q9NRA0 1/20 0.33
SPHK1 Q9NYA1 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
FFAR1 O14842 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810908 0.92 PIM1 (0.85) PIM1AKT2MEN1KMT2AMAPT
SCHEMBL811393 0.90 PIM1 (1.00) PIM1AKT2MEN1KMT2AMAPT
SCHEMBL810532 0.88 PIM1 (0.79) PIM1AKT2MEN1KMT2AMAPT
SCHEMBL810203 0.88 PIM1 (0.79) PIM1AKT2MEN1KMT2AMAPT
SCHEMBL810855 0.86 PIM1 (0.64) PIM1AKT2MAPT
SCHEMBL810799 0.86 PIM1 (0.75) PIM1AKT2MEN1KMT2AMAPT
SCHEMBL810707 0.86 PIM1 (0.73) PIM1AKT2MEN1KMT2AMAPT
SCHEMBL810244 0.85 PIM1 (0.72) PIM1AKT2MEN1KMT2AMAPT
SCHEMBL811128 0.85 PIM1 (0.74) PIM1AKT2MEN1KMT2AMAPT
SCHEMBL810188 0.85 PIM1 (0.73) PIM1AKT2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MEN1 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.